Previous 10 | Next 10 |
2024-06-24 18:30:03 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for ALNY on June 24, 2024 04:25PM ET. The previous analyst recommendation was Equal-Weight. ALNY was trading at $222.9 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $118.11 on volume of 457,565,587 shares Agrify Corporation (AGFY) rose 68.7% to $0.4251 on volume of 291,898,257 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 13.7% to $0.3662 on volume...
2024-06-24 16:00:09 ET Andrew Galler from Morgan Stanley issued a price target of $250.00 for ALNY on 2024-06-24 12:28:00. The adjusted price target was set to $250.00. At the time of the announcement, ALNY was trading at $224.7. The overall price target consensus is at ...
2024-06-24 13:25:16 ET More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Innate falls on updated phase 1/2 data on blood cancer asset...
2024-06-24 13:00:05 ET Patrick Trucchio from H.C. Wainwright issued a price target of $400.00 for ALNY on 2024-06-24 11:29:00. The adjusted price target was set to $400.00. At the time of the announcement, ALNY was trading at $227.05. The overall price target consensus i...
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is one of today's top gainers. The company's shares have moved 37.68% on the day to $228.13. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic ...
2024-06-24 11:37:31 ET Summary HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and...
2024-06-24 11:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for ALNY on June 24, 2024 09:18AM ET. The previous analyst recommendation was Outperform. ALNY was trading at $217.4775 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-06-24 11:03:25 ET Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220. Why is it sign...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...